Europe Approves Avapritinib for Rare Mast Cell Disease Europe Approves Avapritinib for Rare Mast Cell Disease

The drug targets a mast cell mutation that gives rise to indolent systemic mastocytosis, a rare and debilitating blood disorder.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news